Furthermore, since the role of VEGF-D has been established in lymphangiogenesis and is deemed secondary in tumor blood neoangiogenesis, less attention has been devoted to the development of specific VEGF-D inhibitors. This evidence concerns the gene VEGFD and neoplasm.